Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of...

Full description

Bibliographic Details
Main Authors: Milos Holanek, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal, Katarina Petrakova, Marek Svoboda, Alexandr Poprach
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
triple-negative breast cancer
neoadjuvant chemotherapy
early clinical response
pathological complete response
<i>brca</i> mutation
platinum salts
Online Access:https://www.mdpi.com/2072-6694/13/7/1586

Similar Items

Similar Items